Molecular Therapy — Nucleic AcidsBioengineeringPeer-reviewed journal article
AAVone: A Cost-Effective, Single-Plasmid Solution for Efficient AAV Production with Reduced DNA Impurities
Rongze Yang, Ngoc Tam Tran, Taylor J Chen, Mengtian Cui, Yuyan WangiD, Tapan SharmaiD, Boping LiuiD, Jiantao ZhangiD, Xinxu YuaniD, Dengwei Zhang, Cuiping Chen, Zhen Shi, Lemin WangiD, Yuling DaiiD, Haniya Zaidi, Jiarui LiangiD, May W. CheniD, Dabbu Kumar JaijyaniD, Huan HuiD, Bing WangiD, Cheng XuiD, Wenhui HuiD, Guangping GaoiD, Daozhan Yu, Phillip W.L. TaiiD, Wang QizhaoiD
Abstract
Currently, the most common approach for manufacturing GMP-grade adeno-associated virus (AAV) vectors involves transiently transfecting mammalian cells with three plasmids that carry the essential components for production. The requirement for all three plasmids to be transfected into a single cell and the necessity for high quantities of input plasmid DNA, limits AAV production efficiency, introduces variability between production batches, and increases time and labor costs. Here, we developed an all-in-one, single-plasmid AAV production system, called AAVone. In this system, the adenovirus helper genes (E2A, E4orf6, and VA RNA), packaging genes (rep and cap), and the vector transgene cassette are consolidated into a single compact plasmid with a 13-kb backbone. The AAVone system achieves a two- to four-fold increase in yields compared to the traditional triple-plasmid system. Furthermore, the AAVone system exhibits low batch-to-batch variation and eliminates the need for fine-tuning the ratios of the three plasmids, simplifying the production process. In terms of vector quality, AAVs generated by the AAVone system show similar in vitro and in vivo transduction efficiency, but a substantial reduction in sequences attributed to plasmid backbones and a marked reduction in non-functional snap-back genomes. In Summary, the AAVone platform is a straightforward, cost-effective, and highly consistent AAV production system - making it particularly suitable for GMP-grade AAV vectors.
- Citations
- 15
- FWCI
- 8.82
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated Continuous Biomanufacturing of Recombinant Adeno-Associated Virus
Ralf Plieninger, Julia M Mueller, … Thomas K. Villiger·bioRxiv·Sep 17, 2026
- Popularizing recombinant baculovirus-derived OneBac system for scaling-up production of all recombinant adeno-associated virus vector serotypes
- Continuous Production of Recombinant Adeno-Associated Virus in the Insect Cell/Baculovirus Expression Vector System
John Joseph, Francesco Destro, … Stacy L. Springs·Molecular Therapy AdvancesPeer-reviewed·May 1, 2026
- MuteFree: A novel AAV vector system featuring mutation-free ITRs
Silk J. Shi, Yingjun Lin, … Bruce T. Lahn·bioRxiv·Apr 9, 2026
- Precision DNA Impurity Reduction Approaches for Ultra-Pure rAAV Manufacturing
Jingluan Han, Huan Chen, … Huapeng Li·bioRxiv·Apr 7, 2026
- Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Mario Mietzsch, Courtnee Eddington, … Mavis Agbandje‐McKenna·Journal of VirologyPeer-reviewed·Jul 21, 2021